Evidence map›Paper›PMID 35990007›Full record

ArticleACS pharmacology & translational science2022

Comparison of the Tissue Distribution of a Long-Circulating Glucagon-like Peptide-1 Agonist Determined by Positron Emission Tomography and Quantitative Whole-Body Autoradiography.

Eduardo Felipe Alves Fernandes, Jonas Wilbs, Rene Raavé, Christian Borch Jacobsen, Hanne Toftelund, Hans Helleberg, Milou Boswinkel, Sandra Heskamp, Magnus Bernt Frederik Gustafsson, Inga Bjørnsdottir

Open access · greenAbstract read
In one paragraph

Article in ACS pharmacology & translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Spatial Distribution of Brain PET Tracers by MALDI Imaging.Journal of the American Society for Mass Spectrometry · 2025
    Article
  2. New Long-Acting [Journal of medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Eduardo Felipe Alves FernandesGlobal Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.ORCID https://orcid.org/0000-0003-3406-1357
Jonas WilbsGlobal Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.
Rene RaavéRadboudumc, Department of Medical Imaging - Nuclear Medicine, Radboud Institute for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands.
Christian Borch JacobsenIsotope Chemistry, CMC Development, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.ORCID https://orcid.org/0000-0002-7502-9831
Hanne ToftelundGlobal Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.
Hans HellebergGlobal Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.
Milou BoswinkelRadboudumc, Department of Medical Imaging - Nuclear Medicine, Radboud Institute for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands.
Sandra HeskampRadboudumc, Department of Medical Imaging - Nuclear Medicine, Radboud Institute for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands.ORCID https://orcid.org/0000-0001-7250-0846
Magnus Bernt Frederik GustafssonGlobal Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.
Inga BjørnsdottirGlobal Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv, Denmark.
Novo Nordisk (Denmark) · DKRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Positron emission tomography (PET) is a molecular imaging modality that enables non-invasive visualization of tracer distribution and pharmacology. Recently, peptides with long half-lives allowed once-a-week dosing of glucagon-like peptide-1 receptor (GLP-1R) agonists with therapeutic applications in diabetes and obesity. PET imaging for such long-lived peptides is hindered by the typically used short-lived radionuclides. Zirconium-89 (

Identifiers

PMID35990007
PMCPMC9380726
OpenAlexW4283740466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.